Novel Antibody/Peptide R&D Services to Expedite Research on Toxoplasmosis Diagnosis and Treatment

July 29 02:59 2022
With the self-established AntInfectTM Platform, Creative Biolabs offers one-stop services on functional antibody and peptide development for parasitic diseases, such as Toxoplasmosis.

New York, USA – July 28, 2022 – Human Toxoplasma infections have significant public health consequences given the fact that most animal species can harbor the parasite and one-third of the human population has been infected, as well as the devastating sequelae observed after congenital infections, such as blindness. As it presents an urgency to fight against this parasite, global researchers are dedicated to developing antibodies and peptides for Toxoplasma diagnosis and treatment.

As an active player in the field of custom biomolecule discovery services, Creative Biolabs has established a powerful AntInfectTM Platform, which brings state-of-the-art technology to support functional antibody and peptide development for parasitic diseases, such as Toxoplasmosis.

• An Introduction to AntInfectTM Platform

The AntInfect™ Platform being of high sensitivity and high throughput is specially designed for biomolecular development against infectives.

For anti-parasite antibody development, the scientist team has gathered antigen-specific B lymphocytes cytometry technology, hybridoma technology, and phage display technology into the platform to provide access to tailored strategies for different targets.

For antimicrobial peptide (AMP) discovery, Creative Biolabs has announced a package of premade peptide libraries for AMP discovery. The platform is applicable to peptide library construction and screening, peptide array design and scalable, as well as the reproducible photolithographic synthesis of high-quality peptide arrays to facilitate clients’ projects on AMP discovery.

• Toxoplasma-Targeted Antibody/Peptide Discovery Services

Scientists at Creative Biolabs have gained a deep understanding of hot targets for antibody development, including surface protein SAG1 and related sequence family (SRS), SAG2, and SAG3, in applications of diagnosis, therapy, and infection inhibition.

The team also offers the one-stop AMP discovery service for the purpose of exploiting mechanisms such as autophagic- or apoptotic-like processes to kill different developmental stages of a single protozoal species. It is supported by epitope mapping service, phage display technology, and high-density peptide array technology.

The service on the discovery of antibody/peptide targeting Toxoplasma is featured by precise analysis of the sequences of epitope-based antigens, single and combined antigens as capturers, and competitive and affordable price.

Other kinds of parasites covered by the AntInfect™ Platform include Brugia, Cryptosporidium, Eimeria, Fasciola, Leishmania, Neospora, Plasmodium, Schistosoma, Strongyloides, Taenia, and Trypanosoma.

Find more information on Creative Biolabs’ official website

About Creative Biolabs

As a leading custom service provider in antibody development and engineering, Creative Biolabs has established cutting-edge technologies to support functional biomolecule development for infectious diseases. The service portfolio is comprised of anti-infective antibody and peptide discovery and small molecule drug discovery for a wide range of virus, bacterial, and parasite infections.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States